Sapient Capital LLC Reduces Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Sapient Capital LLC cut its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 56.6% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 3,540 shares of the biotechnology company’s stock after selling 4,615 shares during the quarter. Sapient Capital LLC’s holdings in Sarepta Therapeutics were worth $430,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. CIBC Asset Management Inc increased its holdings in Sarepta Therapeutics by 3.3% during the 3rd quarter. CIBC Asset Management Inc now owns 2,712 shares of the biotechnology company’s stock worth $339,000 after purchasing an additional 86 shares during the last quarter. UMB Bank n.a. increased its holdings in Sarepta Therapeutics by 36.0% during the 4th quarter. UMB Bank n.a. now owns 521 shares of the biotechnology company’s stock worth $63,000 after purchasing an additional 138 shares during the last quarter. Oppenheimer Asset Management Inc. increased its holdings in shares of Sarepta Therapeutics by 3.4% in the 3rd quarter. Oppenheimer Asset Management Inc. now owns 4,457 shares of the biotechnology company’s stock valued at $557,000 after acquiring an additional 145 shares during the last quarter. Nisa Investment Advisors LLC increased its holdings in shares of Sarepta Therapeutics by 16.9% in the 3rd quarter. Nisa Investment Advisors LLC now owns 1,070 shares of the biotechnology company’s stock valued at $134,000 after acquiring an additional 155 shares during the last quarter. Finally, MassMutual Private Wealth & Trust FSB increased its holdings in shares of Sarepta Therapeutics by 169.6% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 156 shares during the last quarter. 86.68% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on SRPT shares. Royal Bank of Canada reiterated an “outperform” rating and issued a $182.00 price target on shares of Sarepta Therapeutics in a report on Monday, October 21st. Robert W. Baird lowered their price target on Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating for the company in a report on Thursday, November 7th. Cantor Fitzgerald upgraded Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and boosted their price target for the company from $152.00 to $167.00 in a report on Thursday, November 7th. HC Wainwright reiterated a “sell” rating and issued a $75.00 price target on shares of Sarepta Therapeutics in a report on Thursday, January 30th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $202.00 price target on shares of Sarepta Therapeutics in a report on Monday, January 27th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $176.77.

Sarepta Therapeutics Trading Down 2.7 %

Shares of SRPT stock opened at $109.68 on Wednesday. The stock has a 50-day simple moving average of $120.49 and a 200 day simple moving average of $125.33. Sarepta Therapeutics, Inc. has a fifty-two week low of $102.15 and a fifty-two week high of $173.25. The stock has a market capitalization of $10.48 billion, a P/E ratio of 87.74 and a beta of 0.75. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93.

Insider Activity

In other news, Director Kathryn Jean Boor sold 1,636 shares of the company’s stock in a transaction on Thursday, December 5th. The stock was sold at an average price of $125.55, for a total transaction of $205,399.80. Following the completion of the sale, the director now directly owns 5,880 shares of the company’s stock, valued at $738,234. This represents a 21.77 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the company’s stock in a transaction on Thursday, December 12th. The shares were sold at an average price of $124.84, for a total value of $1,310,820.00. Following the sale, the director now directly owns 22,840 shares of the company’s stock, valued at approximately $2,851,345.60. This represents a 31.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.70% of the stock is currently owned by company insiders.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.